2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

Panel Members

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

Original languageEnglish (US)
Pages (from-to)1573-1588
Number of pages16
JournalAnnals of Oncology
Volume26
Issue number8
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Molecular Pathology
Neoplasms
Biomarkers
Guidelines

Keywords

  • ESMO
  • Locally advanced
  • Non-small-cell lung cancer
  • Recommendations
  • Stage III

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

2nd ESMO Consensus Conference in Lung Cancer : Locally advanced stage III non-small-cell lung cancer. / Panel Members.

In: Annals of Oncology, Vol. 26, No. 8, 01.01.2015, p. 1573-1588.

Research output: Contribution to journalArticle

@article{6f6536df454e4eb4bffdd93c122f9b96,
title = "2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer",
abstract = "To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.",
keywords = "ESMO, Locally advanced, Non-small-cell lung cancer, Recommendations, Stage III",
author = "{Panel Members} and Eberhardt, {Wilfried E.E.} and {De Ruysscher}, Dirk and Walter Weder and {Le P{\'e}choux}, Cecile and {De Leyn}, Paul and H. Hoffmann and Virginie Westeel and Rolf Stahel and Enriqueta Felip and Solange Peters and Keith Kerr and Benjamin Besse and Johan Vansteenkiste and Martin Edelman and Tony Mok and Ken O'Byrne and Silvia Novello and Lukas Bubendorf and Antonio Marchetti and Paul Baas and Martin Reck and Konstantinos Syrigos and Luis Paz-Ares and Smit, {Egbert F.} and Peter Meldgaard and Alex Adjei and Marianne Nicolson and Lucio Crin{\`o} and {Van Schil}, Paul and Suresh Senan and Corinne Faivre-Finn and Gaetano Rocco and Giulia Veronesi and Douillard, {Jean Yves} and Eric Lim and Christophe Dooms",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/annonc/mdv187",
language = "English (US)",
volume = "26",
pages = "1573--1588",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - 2nd ESMO Consensus Conference in Lung Cancer

T2 - Locally advanced stage III non-small-cell lung cancer

AU - Panel Members

AU - Eberhardt, Wilfried E.E.

AU - De Ruysscher, Dirk

AU - Weder, Walter

AU - Le Péchoux, Cecile

AU - De Leyn, Paul

AU - Hoffmann, H.

AU - Westeel, Virginie

AU - Stahel, Rolf

AU - Felip, Enriqueta

AU - Peters, Solange

AU - Kerr, Keith

AU - Besse, Benjamin

AU - Vansteenkiste, Johan

AU - Edelman, Martin

AU - Mok, Tony

AU - O'Byrne, Ken

AU - Novello, Silvia

AU - Bubendorf, Lukas

AU - Marchetti, Antonio

AU - Baas, Paul

AU - Reck, Martin

AU - Syrigos, Konstantinos

AU - Paz-Ares, Luis

AU - Smit, Egbert F.

AU - Meldgaard, Peter

AU - Adjei, Alex

AU - Nicolson, Marianne

AU - Crinò, Lucio

AU - Van Schil, Paul

AU - Senan, Suresh

AU - Faivre-Finn, Corinne

AU - Rocco, Gaetano

AU - Veronesi, Giulia

AU - Douillard, Jean Yves

AU - Lim, Eric

AU - Dooms, Christophe

PY - 2015/1/1

Y1 - 2015/1/1

N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

KW - ESMO

KW - Locally advanced

KW - Non-small-cell lung cancer

KW - Recommendations

KW - Stage III

UR - http://www.scopus.com/inward/record.url?scp=84941599354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941599354&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv187

DO - 10.1093/annonc/mdv187

M3 - Article

C2 - 25897013

AN - SCOPUS:84941599354

VL - 26

SP - 1573

EP - 1588

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -